title: Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.
abstract: Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly increased the maximal peak height of the clot lysis curve, indicating a change in clot structure. In this study Lp(a) is not related to the development of T2DM but may affect clot structure ex vivo without a prolongation of the clot lysis time.
authors.affiliation: AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden.
authors.forename: Marianne
authors.initials: M
authors.lastname: Månsson
authors.affiliation: AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden.
authors.forename: Inge
authors.initials: I
authors.lastname: Kalies
authors.affiliation: Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, University of Gothenburg, S-41345 Göteborg, Sweden.
authors.forename: Göran
authors.initials: G
authors.lastname: Bergström
authors.affiliation: Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, University of Gothenburg, S-41345 Göteborg, Sweden.
authors.forename: Caroline
authors.initials: C
authors.lastname: Schmidt
authors.affiliation: AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden.
authors.forename: Anne
authors.initials: A
authors.lastname: Legnehed
authors.affiliation: Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, University of Gothenburg, S-41345 Göteborg, Sweden.
authors.forename: Lillemor Mattsson
authors.initials: LM
authors.lastname: Hultén
authors.affiliation: AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden.
authors.forename: Lena
authors.initials: L
authors.lastname: Amrot-Fors
authors.affiliation: AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden.
authors.forename: David
authors.initials: D
authors.lastname: Gustafsson
authors.affiliation: 1] AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden [2].
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Knecht
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D025901:Carboxypeptidase B2 / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism
chemical_list: D017270:Lipoprotein(a); D017395:Plasminogen Activator Inhibitor 1; D025901:Carboxypeptidase B2